Embecta (EMBC) reported $1.1B in revenue for fiscal 2025, −3.8% year on year. That ranks #1728 by revenue among 2853 SEC filers and #158 in Healthcare. Net income was $95.4M, a net margin of 8.8%. Revenue has declined 0.1% a year on average since 2020 ($1.1B then). The fiscal 2025 balance sheet shows $1.1B in total assets, $201M in cash and $1.4B in long-term debt.

Key figures

$1.1B2020$1.2B2021$1.1B2022$1.1B2023$1.1B2024$1.1B2025
Embecta — Key figures
Key figuresFY2025YoYSource
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$1.1B−3.8%FY20252025-09-30
Gross profitGrossProfit$677M−7.9%FY20252025-09-30
Operating incomeOperatingIncomeLoss$242M+45.1%FY20252025-09-30
Net incomeNetIncomeLoss$95.4M+21.8%FY20252025-09-30
Operating cash flowNetCashProvidedByUsedInOperatingActivities$192M+437.0%FY20252025-09-30
Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment$9.3M−41.1%FY20252025-09-30
Total assetsAssets$1.1B−7.5%FY20252025-12-31
Shareholders' equityStockholdersEquity−$613M+$156MFY20252025-12-31
CashCashAndCashEquivalentsAtCarryingValue$201M−4.1%FY20252025-12-31
Long-term debtLongTermDebtNoncurrent$1.4B−11.8%FY20252025-12-31

Revenue is total net sales for the fiscal year, taken from each company's own annual filing.

Reported since the last full year

Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.

Embecta — Reported since the last full year
QuarterRevenueNet incomeSource
Q1 20262026-03-31$222M−$4.1MOpen →
Q2 20262026-06-30$272M$21.1MOpen →

Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.

Where this sits in its sector

Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.

Embecta — Where this sits in its sector
Where this sits in its sectorFY2025Position in sector
Net marginRank 62 of 161 companies compared8.8%
Operating marginRank 28 of 160 companies compared22.4%
R&D as share of revenueRank 86 of 102 companies compared3.5%
Cash as share of revenueRank 58 of 160 companies compared18.6%

All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.

Profile

Legal name
Embecta Corp.
Ticker
EMBC
Exchange
Nasdaq
SIC classification
Surgical & Medical Instruments & Apparatus (3841)
Fiscal year end
09-30
CIK
0001872789

Filings

Similar in size, same sector

CompanyRevenueNet income
Sotera HealthSHC$1.2B$77.9M
NovavaxNVAX$1.1B$440M
Prestige Consumer HealthcarePBH$1.1B$190M
EmbectaEMBC$1.1B$95.4M
Acadia PharmaceuticalsACAD$1.1B$391M
Legend BiotechLEGN$1.0B−$297M
Tandem Diabetes CareTNDM$1.0B−$205M

See the full ranking →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Embecta — Key figures |url=https://companiesranked.com/en/company/embecta |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Embecta — Key figures. CompaniesRanked. https://companiesranked.com/en/company/embecta

BibTeX

@misc{companiesranked-en-company-embecta-2026,
  author       = {{CompaniesRanked}},
  title        = {{Embecta — Key figures}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/embecta}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.